Mr. Scott Cormack has over two decades of diverse experience in the biotechnology industry in executive management and venture capital.
Scott is the founding President and CEO of OncoGenex Technologies Inc. and became its full-time President and CEO in January, 2002. He has led OncoGenex through significant corporate milestones including serial rounds of private financing; leading the corporation through transition from pre-clinical through completion of multiple phase 2 clinical trials and through the development of a robust product candidate pipeline. In August, 2008 OncoGenex Technologies Inc. completed a successful reverse take over of Sonus Pharmaceuticals, Inc. to become a NASDAQ listed biotechnology company with Scott becoming the Chief Executive Officer of OncoGenex Pharmaceuticals, Inc.
In October, 2009, Scott was named Canada's Pacific Ernst & Young's Entrepreneur of the Year®, a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses. In December, 2009, Scott led his team to complete a global collaboration and license agreement with global generic medicines giant, Teva Pharmaceutical Industries Ltd., to support the final stage of development of OGX-011. Scott has created a solid foundation for OncoGenex to maximize the broad potential of OGX-011 and a robust pipeline of product candidates, potentially bringing important treatment options to cancer patients.
Dr. Cindy Jacobs Ph.D, MD
Executive Vice President and Chief Medical Officer
Dr. Jacobs is Executive Vice President and Chief Medical Officer at OncoGenex. She received her Ph.D. from Washington State University and her MD from the University of Washington Medical School. She has over twenty years of biotechnology experience in preclinical development, pharmacokinetic/drug metabolism studies, toxicology studies, Phase 1-4 clinical trials in a variety of therapeutic areas, regulatory affairs, biostatistics, data management, medical information and quality assurance. At Immunex (now known as Amgen), Dr. Jacobs successfully lead the preclinical development of soluble cytokine receptors and fusion proteins into the clinic which later resulted in the approval of the TNF Receptor Fusion protein for use in rheumatoid arthritis, currently on the market as Enbrel. Subsequently, she became Vice-President of Clinical Research at CellPro Inc. and coordinated an international team achieving both European and US approvals of the CEPRATE SC Stem Cell System for use in bone marrow and peripheral blood transplantation. Her team achieved two US approvals for the CEPRATE SC System, as a device in combination with a monoclonal antibody for selection of CD34+ cells. Prior to joining OncoGenex, Dr. Jacobs was the Senior Vice-President of Clinical Development and Chief Medical Officer at Corixa (now a subsidiary of Glaxo-Smith-Kline). During her six years at Corixa, her team obtained Canadian approval for Melacine, a cancer vaccine for Melanoma, and two US approvals for BEXXAR, a radioimmunotherapy for refractory and relapsed non-Hodgkin's lymphoma.
Dr. Monica Krieger Ph.D
Vice President of Regulatory Affairs
Dr. Krieger is Vice President, Regulatory Affairs at OncoGenex. She received a Ph.D from Rutgers University and an MBA from the Darden School at the University of Virginia. Her 24 years of experience in regulatory and clinical affairs includes 23 years at five biotechnology companies in Seattle. At Genetic Systems Corporation (currently owned by BioRad Laboratories) she was Vice President, Regulatory, Clinical and Quality Assurance. During her nine years there she led a team that obtained approval for blood banking tests for HIV-1, HIV-2 and hepatitis, as well as approval of other tests for infectious disease. Subsequently she spent seven years at CellPro, Inc. where she worked with Dr. Jacobs to obtain two approvals from the FDA for the CEPRATE ® SC, a stem cell selection device. The first approval was based on data from patients with breast cancer and the second demonstrated the utility of the device in tumour removal in patients with multiple myeloma. At NeoRx, Dr. Krieger led the regulatory group developing two oncology products: one for the treatment of non-Hodgkin's lymphoma and the second for multiple myeloma. Most recently, she spent six years at Corixa Corporation as Vice-President, Regulatory Affairs. There she worked with Dr. Jacobs, and the clinical/regulatory team obtained Canadian approval for Melacine, a vaccine for the treatment of melanoma as well as two US approvals for BEXXAR, a radioimmunotherapy for non-Hodgkin's lymphoma.
Cameron Lawrence
Principal Financial Officer
Cameron Lawrence, 30, has served as the Company's Principal Financial Officer since February 2010, and has served as Director of Financial Reporting since October 2008. From 2003 to 2008, Mr. Lawrence served in various positions at PricewaterhouseCoopers LLP including Manager in the Audit and Assurance Group. Mr. Lawrence holds a Bachelor of Business Administration degree from Simon Fraser University and Master of Professional Accounting degree from the University of Saskatchewan. He is a Chartered Accountant.
Martin Gleave MD, FRCSC, FACS
Chief Scientific Advisor
Martin Gleave, M.D., 51, is a consultant of OncoGenex Technologies and its Chief Scientific Advisor, previously serving as contract Chief Scientific Officer from May 2000 to March 2010. Dr. Gleave is co-founder of OncoGenex Technologies and the principal inventor of its product candidates, OGX-011, OGX-427, and OGX-225. He also served as a director of OncoGenex Technologies prior to the reverse takeover of Sonus Pharmaceuticals. Dr. Gleave is a Distinguished Professor and Director of Research in the Department of Urologic Sciences at the University of British Columbia ("UBC"), the British Columbia Leadership Chair in Prostate Cancer Research, and a consultant Urologist for the Department of Urology at the University of Washington. Dr. Gleave is a Senior Research Scientist and Director of the Vancouver Prostate Center, a UBC and National Centre of Excellence and internationally respected integrated prostate cancer research and treatment facility. Dr. Gleave's major research focus involves the study of cellular and molecular mechanisms mediating acquired treatment resistance in prostate and other cancers, and use of this information to develop integrated multimodality therapies that specifically target these mechanisms. Dr. Gleave directs a translational cancer research program spanning target discovery, validation, credentialization, and therapeutic development and has characterized the functional role of many survival genes in cancer progression, leading to several patented targeted inhibitors. Dr. Gleave received his M.D. from the University of British Columbia in 1984, his Fellow at the Royal College of Surgeons of Canada (FRCSC) in 1989, his Urologic Oncology Fellowship, University of Texas MD Anderson Cancer Center in 1992 and Fellow of the American College of Surgeons (FACS) in 1998.
Jack Goldstein, Ph.D., 62, has served as Chairman of the Board of Directors of the Company since March 2010. Dr. Goldstein was president and Chief Operating Officer of Chiron Corporation until its acquisition by Novartis in April 2006. Before Chiron, he spent two years as a general partner at Windamere Venture Partners, preceded by four years at Applied Imaging Corporation, first as president and Chief Executive Officer and later as chairman. Dr. Goldstein spent over a decade at Ortho Diagnostic Systems, a Johnson & Johnson company, in various executive positions, including four years as president. He was earlier vice president of research and development at a division of Baxter Healthcare Corporation. Dr. Goldstein earned a bachelor of art degree in biology from Rider University, a Master of Science degree in immunology, and doctorate in microbiology from St. John's University. He currently sits on the board of directors of Accuray, Inc., and Orasure Technologies Inc. The determination was made that Dr. Goldstein should serve on our Board of Directors as a result of his extensive experience as a senior executive and as a chair of both publicly held and privately held biotechnology or pharmaceutical company boards of directors.
Ms. Burris was appointed as a director of Sonus in May 2004. Ms. Burris is currently Senior Vice President and Chief Financial Officer of Trubion Pharmaceuticals, Inc, a position she has held since February 2006. From August 2005 to January 2006, Ms. Burris served as Senior Vice President and Chief Financial Officer at Dendreon Corporation. From January 2001 to July 2005, she served as Senior Vice President and Chief Financial Officer at Corixa Corporation, which was sold to GlaxoSmithKline in 2005. Ms. Burris had worked at Corixa since its inception in 1994, and prior to her last position at the firm, had served in various capacities of increasing responsibility in finance and operations. Prior to Corixa, Ms. Burris held several finance and strategic planning positions at The Boeing Company. Ms. Burris is on the Advisory Board of Albers School of Business and Economics at Seattle University. She received a Post Graduate Certificate in accounting and an MBA from Seattle University, and a B.S. from George Mason University. Ms. Burris received her Certified Public Accountant Certification from the State of Washington; however, she is no longer an active CPA.
Dr. Clendeninn served as Corporate Vice President, Head of Clinical Affairs of Agouron Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., from 1993 until his retirement in 2001. With Agouron, Dr. Clendeninn was responsible for development and growth of the Clinical Development Department from pre-clinical phase to phase IV, rapid delivery to market for Viracept, an HIV Protease Inhibitor. Under his leadership, the department grew to over 200 MDs, Ph.Ds and clinical pharmacologists, biostatisticans, data management group and a post marketing medical team. Previous to Agouron, Dr. Clendeninn served as Director of the Clinical Oncology Department for Burroughs Wellcome Company. His other past positions include assistant clinical professor in oncology at the University of North Carolina, senior staff member at the National Cancer Institute, and other general practice and academic-based positions. Dr. Clendeninn has led extensive research in areas that include chemotherapeutic multi-drug resistance, opiate receptors and photochemistry. He has written and co-authored numerous publications including, "The Approach to the Pre-clinical and Clinical Development of a Selective Matrix Metalloprotease Inhibitor (MMP); Prinomastat (AG3340)", July 2000. Dr. Clendeninn currently serves on the boards of Oncogenex Technologies Inc. and on the Board of Scientific Advisors for the National Cancer Institute. Dr. Clendeninn holds a BA Biology/Chemistry from Wesleyan University, CT, and a Ph.D Microbiology/Pharmacology and MD from New York University, NY.
Mr. Scott Cormack has over two decades of diverse experience in the biotechnology industry in executive management and venture capital.
Scott is the founding President and CEO of OncoGenex Technologies Inc. and became its full-time President and CEO in January, 2002. He has led OncoGenex through significant corporate milestones including serial rounds of private financing; leading the corporation through transition from pre-clinical through completion of multiple phase 2 clinical trials and through the development of a robust product candidate pipeline. In August, 2008 OncoGenex Technologies Inc. completed a successful reverse take over of Sonus Pharmaceuticals, Inc. to become a NASDAQ listed biotechnology company with Scott becoming the Chief Executive Officer of OncoGenex Pharmaceuticals, Inc.
In October, 2009, Scott was named Canada's Pacific Ernst & Young's Entrepreneur of the Year®, a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses. In December, 2009, Scott led his team to complete a global collaboration and license agreement with global generic medicines giant, Teva Pharmaceutical Industries Ltd., to support the final stage of development of OGX-011. Scott has created a solid foundation for OncoGenex to maximize the broad potential of OGX-011 and a robust pipeline of product candidates, potentially bringing important treatment options to cancer patients.
Martin Mattingly
Since November 2007, Dr. Mattingly has served as the Chief Executive Officer and member of the board of directors of Trimeris, Inc. Prior to that time, Dr. Mattingly was employed at Ambrx, Inc. where he served as President and Chief Executive Officer from 2005 to 2007. Prior to that, Dr. Mattingly served as Executive Vice President and Chief Operating Officer at CancerVax from 2003 to 2005. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. ("Agouron") and Pfizer, Inc. ("Pfizer"). These assignments included General Manager of the Agouron HIV division; Vice President, Product Development Group at Pfizer; and Vice President, Global Marketing Planning at Pfizer. From 1983 to 1996, Dr. Mattingly held various positions in oncology marketing and sales management at Eli Lilly and Company. Dr. Mattingly holds a Doctor of Pharmacy degree from the University of Kentucky.
Stewart Parker, 54, has served as a director of the Company since March 2010. Ms. Parker managed the formation of Targeted Genetics as a wholly owned subsidiary of Immunex Corporation (Immunex was subsequently acquired by Amgen) and served as president, Chief Executive Officer and a director of Targeted Genetics since its spinout from Immunex in 1992 to 2008. She served in various capacities at Immunex from August 1981 through December 1991, most recently as vice president, corporate development. Ms. Parker also served as president and a director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products, from February 1991 to January 1993. She has served on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry, and as a director of several privately held companies. Ms. Parker received her B.A. and M.B.A. from the University of Washington. The determination was made that Ms. Parker should serve on our Board of Directors due to her executive leadership experience in development stage clinical development, public company expertise, and business development for pharmaceuticals and biologics.
show all
hide all
0.01
